Literature DB >> 35059972

Different strategies for expression and purification of the CT26-poly-neoepitopes vaccine in Escherichia coli.

Zahra Movahed1,2, Elham Sharif1,3, Maryam Ahmadzadeh1, Navid Nezafat4,5, Hoda Jahandar2,6, Elham Mohit7.   

Abstract

BACKGROUND: Due to the association of hypermutated colorectal cancer (CRC) with many neo-antigens, poly-neo-epitopes are attractive vaccines. The molecular features of murine CT26 are similar to those of aggressive human CRC. CT26 contains some antigenic mutations, which can provide specific immunotherapy targets. Herein, we aimed to express, and purify the previously designed hexatope containing CT26 neoepitopes, CT26-poly-neoepitopes. METHODS AND
RESULTS: In the current study, expression of the CT26-poly-neoepitopes was optimized in three different Escherichia coli strains including BL21 (DE3), Origami (DE3), and SHuffle®. Furthermore, the effect of ethanol on the CT26-poly-neoepitopes expression was investigated. The highest amount of CT26-poly-neoepitopes, which included CT26-poly-neoepitopes with the uncleaved pelB signal sequence and the processed one, was achieved when BL21 containing pET-22 (CT26-poly-neoepitopes) was induced with 0.1 mM IPTG for 48 h at 22 ºC in the presence of 2% ethanol. However, 37 ºC was the optimized induction temperature for expression of the CT26-poly-neoepitopes in the absence of ethanol. To purify the CT26-poly-neoepitopes, Ni-NTA affinity chromatography under denaturing and hybrid conditions were applied. High and satisfactory CT26-poly-neoepitopes purity was achieved by the combined urea and imidazole method.
CONCLUSION: The effect of ethanol on expression of the CT26-poly-neoepitopes was temperature-dependent. Furthermore, the pelB-mediated translocation of the CT26-poly-neoepitopes into the periplasm was inefficient. Moreover, higher concentration of imidazole in the washing buffer improved the CT26-poly-neoepitopes purification under hybrid condition. Overall, the immunogenicity of CT26-poly-neoepitopes expressed in BL21 under the optimum condition and purified under hybrid condition can be studied in our future in vivo study.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  CT26; Colorectal cancer; Ethanol; Neoepitope; Peptide pectate lyase B (PelB); Periplasm; Purification

Mesh:

Substances:

Year:  2022        PMID: 35059972     DOI: 10.1007/s11033-021-06727-w

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  34 in total

1.  Personalized Peptide-based Vaccination for Treatment of Colorectal Cancer: Rational and Progress.

Authors:  Seyed Mostafa Parizadeh; Reza Jafarzadeh-Esfehani; Maryam Ghandehari; Afsaneh Rezaei-Kalat; Seyed Mohammad Reza Parizadeh; Afsane Javanbakht; Seyed Mahdi Hassanian; Gordon A Ferns; Majid Khazaei; Amir Avan
Journal:  Curr Drug Targets       Date:  2019       Impact factor: 3.465

2.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

Review 3.  Towards personalized, tumour-specific, therapeutic vaccines for cancer.

Authors:  Zhuting Hu; Patrick A Ott; Catherine J Wu
Journal:  Nat Rev Immunol       Date:  2017-12-11       Impact factor: 53.106

Review 4.  Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy.

Authors:  Davide Ciardiello; Pietro Paolo Vitiello; Claudia Cardone; Giulia Martini; Teresa Troiani; Erika Martinelli; Fortunato Ciardiello
Journal:  Cancer Treat Rev       Date:  2019-05-04       Impact factor: 12.111

5.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Authors:  Mahesh Yadav; Suchit Jhunjhunwala; Qui T Phung; Patrick Lupardus; Joshua Tanguay; Stephanie Bumbaca; Christian Franci; Tommy K Cheung; Jens Fritsche; Toni Weinschenk; Zora Modrusan; Ira Mellman; Jennie R Lill; Lélia Delamarre
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Design and expression of polytopic construct of cathepsin-L1, SAP-2 and FhTP16.5 proteins of Fasciola hepatica.

Authors:  S Aghamolaei; B Kazemi; M Bandehpour; M M Ranjbar; S Rouhani; A Javadi Mamaghani; S J S Tabaei
Journal:  J Helminthol       Date:  2020-03-04       Impact factor: 2.170

Review 7.  Updates on immunotherapy for colorectal cancer.

Authors:  Aparna Kalyan; Sheetal Kircher; Hiral Shah; Mary Mulcahy; Al Benson
Journal:  J Gastrointest Oncol       Date:  2018-02

8.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

9.  Expression, purification, and renaturation of a recombinant peptide-based HIV vaccine in Escherichia coli.

Authors:  Wei He; Jiayi Shu; Jian Zhang; Zhihua Liu; Jianqing Xu; Xia Jin; Xuedong Wang
Journal:  Can J Microbiol       Date:  2017-01-27       Impact factor: 2.419

10.  A facile approach to enhance antigen response for personalized cancer vaccination.

Authors:  Aileen Weiwei Li; Miguel C Sobral; Soumya Badrinath; Youngjin Choi; Amanda Graveline; Alexander G Stafford; James C Weaver; Maxence O Dellacherie; Ting-Yu Shih; Omar A Ali; Jaeyun Kim; Kai W Wucherpfennig; David J Mooney
Journal:  Nat Mater       Date:  2018-03-05       Impact factor: 43.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.